Aptorum Group Limited, a clinical stage biopharmaceutical company, announced a definitive agreement to merge with DiamiR Biosciences. The all-stock transaction will result in DiamiR becoming a wholly-owned subsidiary of Aptorum Group. Aptorum Group plans to remain listed on the Nasdaq Stock Market after the merger. The collaboration aims to leverage DiamiR's expertise in developing innovative blood-based tests for brain health and other diseases, enhancing the combined company's ability to address unmet medical needs in oncology and infectious diseases. The merger is expected to create a global life sciences company with a strong focus on non-invasive testing for brain health and other complex conditions.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。